NCT07219147 2026-04-20
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
Phase 1 Recruiting
Clinical Trials
18 trialsNCT06982222 2026-04-13
Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT04514484 2026-03-23
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT07145177 2026-03-23
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Recruiting
NCT05245006 2026-03-17
PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer
University of California, San Francisco
Phase 1 Active not recruiting
NCT06305598 2026-02-19
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT05733351 2025-09-15
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Emory University
Phase 1 Terminated
NCT07118176 2025-08-12
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT06942104 2025-07-18
Imaging of Solid Tumors Using 18F-TRX
University of California, San Francisco
Phase 1 Recruiting
NCT04457232 2025-07-15
FAPI PET Prost
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT04927663 2025-05-20
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression
University of California, San Francisco
Phase 1 Terminated
NCT02603965 2025-05-02
Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery
Thomas Jefferson University
Phase 1 Completed
NCT05807126 2024-05-02
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT01174199 2022-10-03
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
Roswell Park Cancer Institute
Phase 1 Terminated
NCT04279561 2022-09-21
Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT01028885 2019-07-25
MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT02429804 2017-05-30
NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer
Stanford University
Phase 1 Terminated
NCT00989105 2012-02-28
Technetium Tc 99m Demobesin-4 for Imaging Procedures in Patients With Prostate Cancer
Cancer Research UK
Phase 1 Terminated